Kallikrein 4 is a proliferative factor that is overexpressed in prostate cancer.
about
Rapid gene expression changes in peripheral blood lymphocytes upon practice of a comprehensive yoga programHypomaturation enamel defects in Klk4 knockout/LacZ knockin miceDirect and indirect mechanisms of KLK4 inhibition revealed by structure and dynamics.TEAD1 and c-Cbl are novel prostate basal cell markers that correlate with poor clinical outcome in prostate cancer.Aberrant KLK4 gene promoter hypomethylation in pediatric hepatoblastomas.Three dysregulated miRNAs control kallikrein 10 expression and cell proliferation in ovarian cancer.The effects of short-term genistein intervention on prostate biomarker expression in patients with localised prostate cancer before radical prostatectomy.Genetic association of the KLK4 locus with risk of prostate cancer.STAMP2 increases oxidative stress and is critical for prostate cancer.Functional characterization of BC039389-GATM and KLK4-KRSP1 chimeric read-through transcripts which are up-regulated in renal cell cancerHigh kallikrein-related peptidase 6 in non-small cell lung cancer cells: an indicator of tumour proliferation and poor prognosis.Clinical significance of kallikrein-related peptidase-4 in oral cancerMolecular circuit involving KLK4 integrates androgen and mTOR signaling in prostate cancer.Prostatic trypsin-like kallikrein-related peptidases (KLKs) and other prostate-expressed tryptic proteinases as regulators of signalling via proteinase-activated receptors (PARs).microRNAs: a new frontier in kallikrein research.DPPI may activate KLK4 during enamel formation.Functional roles of human kallikrein-related peptidases.Prognostic value and biological role of the kallikrein-related peptidases in human malignancies.Targeting kallikrein-related peptidases in prostate cancer.KLK4 silencing inhibits the growth of oral squamous cell carcinoma through Wnt/β-catenin signaling pathway.Kallikrein-related peptidases (KLKs) as emerging therapeutic targets: focus on prostate cancer and skin pathologies.Divergent androgen regulation of unfolded protein response pathways drives prostate cancer.KLK-targeted Therapies for Prostate Cancer.The miRNA-kallikrein axis of interaction: a new dimension in the pathogenesis of prostate cancer.Kallikrein-related peptidase 4 gene (KLK4) in prostate tumors: quantitative expression analysis and evaluation of its clinical significance.Quantification of Human Kallikrein-Related Peptidases in Biological Fluids by Multiplatform Targeted Mass Spectrometry Assays.Dysregulation of kallikrein-related peptidases in renal cell carcinoma: potential targets of miRNAs.Kallikrein-related peptidase 4 (KLK4) initiates intracellular signaling via protease-activated receptors (PARs). KLK4 and PAR-2 are co-expressed during prostate cancer progression.Activation of hepatocyte growth factor activator zymogen (pro-HGFA) by human kallikrein 1-related peptidases.A variant of the KLK4 gene is expressed as a cis sense-antisense chimeric transcript in prostate cancer cells.Polyclonal antibodies against kallikrein-related peptidase 4 (KLK4): immunohistochemical assessment of KLK4 expression in healthy tissues and prostate cancer.Human kallikrein 4 signal peptide induces cytotoxic T cell responses in healthy donors and prostate cancer patients.Pericellular regulation of prostate cancer expressed kallikrein-related peptidases and matrix metalloproteinases by cell surface serine proteases.Kallikrein-related peptidase 4 contributes to the tumor metastasis of oral squamous cell carcinoma.Engineering a potent inhibitor of matriptase from the natural hepatocyte growth factor activator inhibitor type-1 (HAI-1) protein.The first potent diphenyl phosphonate KLK4 inhibitors with unexpected binding kinetics
P2860
Q21090763-9F229B16-1130-41C0-A521-E378AC66EA82Q28509062-CB13E019-B8F1-4047-810F-78C226E5B254Q30825171-8446C2BC-91D0-479C-AE9A-7A16C303E404Q33383797-F9BED732-4B3C-496E-B184-D6E14ED12346Q33597867-8967E364-66E8-45DD-A95E-8F1D8AD6E35EQ33794911-445A1B3A-16C8-48F7-A1DB-ADB12B91393DQ34187693-769C0384-CE76-451F-A674-3E01F307C84EQ34412503-F386CAD6-325B-45FD-B22A-41AEC7F0A241Q35192455-E8C3D650-FDD7-4299-8317-0D01D3830CE0Q35576307-18BDF646-37BA-4FE7-808E-548CB3EFB06EQ35893466-3C457C0A-EFBD-48B1-830B-8E4D858DB1DAQ36079284-6A5C8084-3CF7-4CE0-88D4-8AB3D1A579F8Q37010879-FE67A0A6-EC9C-4587-B8B5-FC6B2DD68653Q37216570-694DF58B-A5D2-46FE-96B5-EA31ECF4A128Q37216598-971896D6-7E8D-45F9-BF02-AA265F282F80Q37341921-D32060A3-90B9-4706-A947-708B01DF93ADQ37612613-EF35FB61-072B-4E94-A81A-B285C1C8F43BQ37690308-51EC4E2C-AC7E-4CE7-BE54-DF92C4FC3D69Q38191293-95C5DCF2-63A6-45D4-BDFF-1176CB36902AQ38718409-4995B424-DCE7-41DC-AB5C-5ACA24D2B5CAQ38760061-6E496B20-061B-4583-8F0F-F0F9FD3F1D4EQ38888506-80A207B8-698A-45B1-AA50-AC2802DB2866Q38967486-F1078949-2EE4-4A4A-8250-38A6FB7B26B4Q39364396-96351891-8A69-4BE4-AAC7-6C0365EDC5EEQ39552861-E8413AEF-0E2E-4B5F-A827-C3ED3CF73293Q39637184-29DC6CF9-1477-4C4B-8A6D-D37CA31E37FAQ39735817-C65A764A-172A-43C7-B989-A1F75A018B76Q40007756-F326B002-3D18-40AF-AABD-1B8D2B64A93FQ40020532-6ED41823-760F-4257-B186-563C0E661D42Q40675548-30A91455-64A0-42DD-9073-BF46136ACF0BQ43716470-5EE09DC1-924F-4042-A095-BDC74E54E558Q44315577-E6536ECA-245D-49D8-888B-0CE1435B7657Q47155746-2F5298DD-2930-4E2F-A3B9-F6D111E3440DQ48029178-2EB306EB-6590-4BA4-812D-A2E3A6428A89Q49545332-A1EC6DD5-E79C-405C-A5DD-5C77B99821D2Q58864166-5D763AF4-D1A0-40D3-A3CE-4D35772022CB
P2860
Kallikrein 4 is a proliferative factor that is overexpressed in prostate cancer.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Kallikrein 4 is a proliferative factor that is overexpressed in prostate cancer.
@en
type
label
Kallikrein 4 is a proliferative factor that is overexpressed in prostate cancer.
@en
prefLabel
Kallikrein 4 is a proliferative factor that is overexpressed in prostate cancer.
@en
P2093
P1433
P1476
Kallikrein 4 is a proliferative factor that is overexpressed in prostate cancer.
@en
P2093
Anette Kilander
Bjørn Risberg
Fahri Saatcioglu
Håkon Waehre
Håvard E Danielsen
Tove Irene Klokk
P304
P356
10.1158/0008-5472.CAN-06-4728
P407
P577
2007-06-01T00:00:00Z